Skip to main content
GutCited

Omega-3 Fatty Acids (EPA/DHA) für Crohn's Disease

C

EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dcrohns\u002Ddisease'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

Fazit

EPIC-1 and EPIC-2 large RCTs showed no benefit for maintaining Crohn's remission. Earlier smaller studies were more positive. Current consensus is neutral.

Key Study Findings

Other
Intestinal anti-inflammatory, histopathologic and anti-oxidative regulatory effects of total alkaloids extract from Linum usitatissimum L. …
Dose: 50, 100, and 200 mg/kg oral vs.: Dexamethasone 2.4 mg/kg; DNBS colitis model vs healthy Outcome: Colonic inflammation markers (MPO, NO, MDA, CAT, GSH) Wirkung: None None

Population: DNBS-induced Crohn's disease BALB/c mouse model

Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None vs.: None Outcome: IBD microbiota modulation and immune regulation Wirkung: None None

Population: IBD patients (review of nutritional interventions)

Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None vs.: None Outcome: Athletic performance and nutritional optimization Wirkung: None None

Population: Vegan athletes (narrative review)

Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None vs.: None Outcome: Diet-genetics interaction in IBD Wirkung: None None

Population: IBD patients (editorial commentary)

Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None vs.: None Outcome: Colitis severity Wirkung: None None

Population: Crohn's disease patients

Observational Study
Evaluating the Effects of Omega-3 Polyunsaturated Fatty Acids on Inflammatory Bowel Disease via Circulating Metabolites: …
Dose: 95% vs.: None Outcome: inflammation markers Wirkung: None None

Population: None

Key Statistics

6

Studien

800

Teilnehmer

Mixed

C

Bewertung

Referenced Papers

Gastroenterology clinics of … 2018 67 Zitierungen
Medical principles and … 2017 45 Zitierungen
European journal of … 2016 79 Zitierungen
Clinics in dermatology 2016 19 Zitierungen
The Cochrane database … 2014 88 Zitierungen
Alimentary pharmacology & … 2013 128 Zitierungen
The British journal … 2012 145 Zitierungen
The Cochrane database … 2012 130 Zitierungen
The Cochrane database … 2009 198 Zitierungen
The Cochrane database … 2007 2 Zitierungen
Gastroenterology nursing : … 2006 24 Zitierungen
Current opinion in … 2005 22 Zitierungen
Journal of the … 2002 2016 Zitierungen
Current opinion in … 2002 1 Zitierungen
Current opinion in … 2002
Zeitschrift fur Gastroenterologie 1998 18 Zitierungen
Arquivos de gastroenterologia 1996

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

general:
1,000-2,000 mg combined EPA/DHA per day
ibdsupport:
2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)

Obergrenze: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

In der Forschung untersuchte Dosierungen

Dosierung Dauer Wirkung N
50, 100, and 200 mg/kg oral -- Positive --
None -- Positive --
None -- Positive --
None -- Neutral --
None -- Neutral --
95% -- Mixed --
None -- Mixed 12194
None -- Mixed --

Beste Einnahmezeit: With meals containing fat for better absorption

Safety & Side Effects

Gemeldete Nebenwirkungen

  • Fishy aftertaste and burping
  • Mild gastrointestinal discomfort (nausea, diarrhea)
  • Potential increased bleeding time at very high doses (>3 g/day)
  • May lower blood pressure slightly

Bekannte Wechselwirkungen

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • Blood pressure medications (additive hypotensive effect)
  • Orlistat (may reduce omega-3 absorption)
  • Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)

Tolerierbare Höchstaufnahmemenge: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Omega-3 Fatty Acids (EPA/DHA) help with Crohn's Disease?
Based on 6 studies with 800 participants, there is limited but promising evidence that Omega-3 Fatty Acids (EPA/DHA) may support Crohn's Disease management. Our evidence grade is C (Some Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Crohn's Disease?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Crohn's Disease?
We rate the evidence as Grade C (Some Evidence). This rating is based on 6 peer-reviewed studies with 800 total participants. The overall direction of effect is mixed.

Related Evidence

Omega-3 Fatty Acids (EPA/DHA) für andere Beschwerden

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.